Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the
Respimat inhaler, once daily for four weeks in patients with chronic obstructive pulmonary
disease (COPD).